CKD-388
/ Chong Kun Dang
- LARVOL DELTA
Home
Next
Prev
1 to 5
Of
5
Go to page
1
September 28, 2022
Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-388(2) in Healthy Subjects
(clinicaltrials.gov)
- P1 | N=65 | Completed | Sponsor: Chong Kun Dang Pharmaceutical | Not yet recruiting ➔ Completed
Trial completion • Hepatitis B • Hepatology • Infectious Disease • Inflammation
January 12, 2022
Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-388(2) in Healthy Subjects
(clinicaltrials.gov)
- P1; N=60; Not yet recruiting; Sponsor: Chong Kun Dang Pharmaceutical
Clinical • New P1 trial • Hepatitis B • Hepatology • Infectious Disease • Inflammation
December 31, 2021
Chong Kun Dang receives approval for three clinical trials at the same time, including glaucoma, hepatitis B, and psoriasis [Google translation]
(Health Korea News)
- "Chong Kun Dang was approved for clinical trials on three of its drugs at the same time...'CKD-388' is effective in treating chronic hepatitis B in adults. This clinical trial is to evaluate the safety and pharmacokinetics of 'CKD-388' in 60 healthy adult subjects. The implementing organizations were known as Bioinfra and H+ Yangji Hospital. "
New trial • Hepatitis B • Infectious Disease
June 15, 2021
Chong Kun Dang develops CKD-388, a drug that responds to 'Vemlidi' [Google translation]
(CEO Score Daily)
- "Chong Kun Dang is speeding up the development of a drug to respond to multinational pharmaceutical company Gilead Sciences' hepatitis B treatment Vemlidi (ingredient name: tenofovir alafenamide hemifumarate)...the reference drug for CKD-388, which Chong Kun Dang is conducting a phase 1 clinical trial, is 'Vemlidi Tablet'...the trial is expected to start in March of this year and end in February next year...The expiration date of the target patent (patent number 10-1612642-0000) for which pharmaceutical companies have requested a patent trial is August 15, 2032."
New P1 trial • Patent • Hepatitis B • Infectious Disease
December 21, 2020
Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-388 in Healthy Subjects
(clinicaltrials.gov)
- P1; N=56; Not yet recruiting; Sponsor: Chong Kun Dang Pharmaceutical
Clinical • New P1 trial • Hepatitis B • Hepatology • Infectious Disease
1 to 5
Of
5
Go to page
1